Studies have shown that LRIG2 participated in the initiation and development of glioma, and promoted cell proliferation through activating the tyrosine kinase and its downstream pathway, also inhibited the spontaneous apoptosis of glioblastoma cells through mitochondrial pathway, and collectively involving in drug resistance [13, 20, 21]. The gene discussed is LRIG2; the disease is central nervous system cancer.